

ASX RELEASE

2 September 2021

AMENDMENT TO SHAREHOLDER INFORMATION INCLUDED IN ANNUAL REPORT

Sydney, 2 September 2021 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, wishes to provide an amendment to the shareholder information included in its 2021 annual report, which was lodged with ASX on Thursday 26 August 2021.

The shareholder information erroneously omitted two shareholdings which are subject to voluntary escrow. The corrected top 20 shareholding list at 17 August 2021 is as follows:

Rank	Name	Number of shares	%
1	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	52,263,824	39.59
2	WILLOUGHBY CAPITAL PTY LTD <WILLOUGHBY CAPITAL A/C>	15,500,000	11.74
3	BNP PARIBAS NOMINEES PTY LTD <AGENCY LENDING DRP A/C>	5,951,957	4.51
4	BNP PARIBAS NOMS PTY LTD <DRP>	5,342,372	4.05
5	CITICORP NOMINEES PTY LIMITED	2,926,720	2.22
6	MNA FAMILY HOLDINGS PTY LTD <HISHENK PTY LTD SUPER A/C>	1,920,000	1.45
7	KILINWATA INVESTMENTS PTY LIMITED	1,793,899	1.36
8	NETWEALTH INVESTMENTS LIMITED <WRAP SERVICES A/C>	1,384,872	1.05
9	BNP PARIBAS NOMINEES PTY LTD ACF CLEARSTREAM	1,316,415	1.00
10	HISHENK PTY LTD	1,295,000	0.98
11	JAMPLAT PTY LTD	1,293,334	0.98
12	MR IAIN ROSS	1,000,001	0.76
13	MR PETER ALAN LUEDEKE + MRS JULIA LUEDEKE <LUEDEKE RETIREMENT FUND A/C>	650,000	0.49
14	MI OK CHONG	597,966	0.45
15	MR FRANCIS SAMSON	570,000	0.43
16	MR TONY MARK ELDRIDGE + MRS ANITA MAREE ELDRIDGE <TM & AM ELDRIDGE SUPER A/C>	555,000	0.42
17	NATIONAL NOMINEES LIMITED	506,172	0.38
18	D & G BROWN INVESTMENTS PTY LIMITED	503,589	0.38
19	C & L JACKSON INVESTMENTS PTY LTD <JACKSON FAMILY S/FUND A/C>	479,001	0.36
20	INVIA CUSTODIAN PTY LIMITED <GSJBW MANAGED A/C>	454,988	0.34
Totals: Top 20 holders of all shareholders		96,305,110	72.95

Further, substantial holdings in the Company's shares at 17 August 2021 should read as follows:

Name	Number of shares	%
WILLOUGHBY CAPITAL PTY LTD <WILLOUGHBY CAPITAL A/C>	15,500,000	11.96
MNA FAMILY HOLDINGS PTY LTD <HISHENK PTY LTD SUPER A/C>	1,920,000	1.48
Platinum International Health Care Fund *	7,084,856	5.47
Quest Asset Partners *	11,101,710	8.40
	35,606,566	27.31

* held via a nominee

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immunology agents. A phase I study is expected to begin in CY2021.

For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.